Auteur: Bart Vanhaesebroeck

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in …

PI3K has become a very intense area of research, with over 2000 publications on PI3K in Pub Med for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, …